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Introduction
Effective interventions are available to reduce the rate of perinatal HIV transmission when women
are identified as HIV infected early in pregnancy. Pregnant women who are HIV infected but who do
not receive prenatal care or do not receive an HIV test during prenatal care are not identified as HIV
infected and therefore miss opportunities to reduce the risk of transmission to their infants and to
receive life-saving treatments for themselves. With the implementation of screening programs using
rapid HIV testing in labor and delivery settings, women with unknown HIV test results during
prenatal care (results not documented in the prenatal medical record) can learn their HIV status
quickly and receive short-course antiretroviral (ARV) prophylaxis to dramatically reduce the risk of
transmitting HIV to their infants. The Centers for Disease Control and Prevention (CDC) recom-
mends routine rapid HIV testing using an opt-out approach for women in labor whose HIV status is
unknown (see Dear Colleague Letter, Appendix A).
As a result of a congressional mandate contained in the Ryan White CARE Act Amendments of 2000
that a study should be conducted of perinatal HIV transmission in the United States, the Office of the
Inspector General (OIG) issued a 2002 report entitled “Reducing Obstetrician Barriers to HIV Test-
ing.”1 One of the recommendations in the report is that “CDC should facilitate the development and
states’ implementation of protocols for HIV testing during labor and delivery in order to promote
testing in this setting as the standard of care.” Implementing rapid testing and short-course ARV
prophylaxis in labor and delivery settings is feasible, but as is true when implementing any new
screening program and clinical intervention, there are challenges. CDC has established a working
group of 10 persons with expertise in obstetrics, pediatrics, public health practice, nursing, health
education and training, blood screening and laboratory science, epidemiology, and rapid HIV testing
technology to develop this model protocol for rapid HIV screening for women in labor. The working
group represents academic institutions and university hospitals, a peer advocacy and support organi-
zation for women living with HIV infection, state and federal health agencies, as well as an interna-
tionally recognized HIV training and education organization. Each member of the group brings
diverse experiences with rapid HIV testing to this document. The committee recognizes that as rapid
HIV testing is more routinely implemented in labor and delivery settings, more knowledge will be
gained. This guide will therefore be maintained as a “living document” and will be regularly updated
and maintained on the CDC Web sites; it can be viewed on the perinatal HIV prevention site
(www.cdc.gov/hiv/projects/perinatal/) and the rapid HIV testing site (www.cdc.gov/hiv/rapid_testing).
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I. Background on Rapid Testing During Labor and Delivery
Tremendous medical and public health achievements have been made in the prevention of mother-to-
child transmission (MTCT) of HIV-1. The risk for infant infection has been reduced from approxi-
mately 25% to less than 2% by the use of currently recommended prenatal ARV and obstetric inter-
ventions for a woman who is aware of her HIV infection early in pregnancy.
Ideally, all women should be screened for HIV before delivery, during an initial prenatal care visit so
that potent combination antiretroviral treatment can be given to women who are HIV-infected.
However, according to the CDC, approximately 40% of the mothers of the estimated 280–370 HIV-
infected infants born in 2000 were not known to have HIV infection before delivery.1 It is critical to
greatly reduce these missed opportunities for identifying HIV-infected pregnant women during the
prenatal period, when the most effective interventions can be delivered.
According to clinical trial data, ARV prophylaxis, even when begun during labor and delivery and
then given to the neonate, can reduce MTCT of HIV as much as 50%.2-6  To maximize this benefit, it
is of utmost importance to obtain HIV test results for women in labor as soon as possible.  Timely
rapid HIV test results may allow providers to avoid some common obstetric practices that may
increase the risk of transmission (e.g., artificial rupture of membranes, amniocentesis, or sampling of
blood from the fetus’s scalp), and they can also advise the mother not to breastfeed.7
Routinely offering rapid HIV testing to women whose HIV status is unknown during labor and
delivery provides the opportunity to reduce transmission even among women who do not seek care
until labor begins. The rapid HIV test kits now licensed in the United States allow test results to be
available in 20 minutes or less. Results from the OraQuick Rapid HIV-1 Antibody Test (OraSure
Technologies, Inc., Bethlehem, Pennsylvania) can be read within 20–40 minutes, and results from the
Reveal Rapid HIV-1 Antibody Test (MedMira Laboratories, Inc., Halifax, Nova Scotia) can be read
in approximately 5–10 minutes after test procedures are begun. Findings from the CDC-sponsored
Mother-Infant Rapid Intervention at Delivery (MIRIAD) study indicate that offering voluntary HIV
testing during labor is feasible in obstetric settings and that the OraQuick Rapid HIV-1 Antibody
Test, used on whole blood specimens, delivers accurate and timely test results.8
The purpose of this document is to offer guidance and practical tips to clinicians, laboratorians,
hospital administrators, and policymakers who are planning and implementing a program for HIV
rapid testing during labor and delivery for women of unknown HIV status and to provide the general
structure of a model rapid HIV testing protocol that can be adapted by staff at facilities that seek to
implement rapid testing during labor and delivery.  For additional background on perinatal HIV
prevention, see References, Other Suggested Reading, and Resources.
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II. Planning and Implementing a Rapid HIV Testing
Program for Women in Labor: Points to Consider in
Preparing to Develop a Rapid HIV Testing Protocol
A.  Location of Testing: in the Laboratory or in the Labor and Delivery Unit?
The U.S. Food and Drug Administration (FDA) recently approved a 1-step rapid HIV test that can be
performed with whole blood either in the laboratory or at the point of care, that is, in the labor and
delivery unit.9 With this test, it is possible to obtain results in as little as 20 minutes from the time the
specimen is collected.  In practice, based on data from the MIRIAD study at 1 site, median turn-
around time for test results was 45 minutes in hospitals where testing was performed in the labor and
delivery unit, and 3 1/2 hours when specimens were sent to the laboratory.10
Deciding where to conduct rapid HIV testing depends on a number of factors, including logistics in
the labor and delivery unit, availability of trained staff, the capacity of the laboratory to consistently
convey rapid HIV test results quickly (optimally in less than 60 minutes),10 and the Clinical Labora-
tory Improvement Act (CLIA) categorization of the test device. The OraQuick Rapid HIV-1 Anti-
body Test is designated by CLIA as waived and can be performed in the labor and delivery unit; the
Reveal Rapid HIV-1 Antibody Test is designated under CLIA as moderate-complexity and must
therefore be performed in a laboratory.
Point-of-care testing requires training and continual supervision to ensure competent and proficient
testing.  This requirement can pose a challenge, especially if staff turnover is high.  When rapid
testing is performed in the laboratory, attaining consistently prompt results requires the availability of
24-hour staff responsive to the urgent need for immediate HIV test results.  Choosing the location for
rapid testing may be best accomplished after a needs assessment during labor and delivery and
consultation with the hospital’s point-of-care testing committee.  (See section IV for the training
essentials for point-of-care testing.) The College of American Pathologists Commission on Labora-
tory Accreditation has published a point-of-care testing checklist, which is used as part of its accredi-
tation process. The checklist, which may help to guide the point-of-care testing process in labor and
delivery settings, is available a ww.cap.org/apps/docs/laboratory_accreditation/checklists/checklistftp.html.
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Provisions, therefore, must be made to confirm all preliminary positive rapid HIV test results, as
soon as possible, with a supplemental test such as the Western blot or immunofluorescent assay
(IFA). However, such testing can take several days or more and does not satisfy the need for timely
HIV test results for women in labor.  Thus, even in optimal rapid testing programs, some women
who are not infected will receive ARV prophylaxis on the basis of a false-positive result from a rapid
HIV test. The seriousness of the psychological effect of such a result is self-evident. However, a
short course of the ARV prophylaxis currently recommended by the US Public Health Service has no
known long-term safety effects for women and infants who are not infected.11  Observational studies
and clinical trials have shown that when ARV prophylaxis is administered during labor or within the
first 12 hours after birth, the risk of perinatal HIV transmission  is reduced from 25% to 9%–13%.2-6
In addition, diagnosing HIV infection during labor and delivery provides a window of opportunity to
offer infected women referral and treatment for their own care.
C. Importance of System to Ensure Labor Staff Access to Prenatal HIV
Test Results
 Experience at several hospitals has shown that HIV testing has often been done during the prenatal
period but that results have not been available to labor and delivery staff.  The lack of access to
prenatal test results thus leads to unnecessary rapid testing and increases the potential for false-
positive results and unnecessary ARV prophylaxis.  During planning for the implementation of a
protocol for rapid testing during labor, it is critical to ensure that all results of HIV testing during
pregnancy are documented in the woman’s prenatal record and readily available to labor and delivery
staff. Ensuring the availability of prenatal results may require coordination with other antenatal
health care facilities to make sure that the pregnant woman signs a medical release and that her
prenatal records are routinely and promptly transferred to the delivery facility before the woman’s
due date.
D. Choosing the Type of Rapid HIV Testing to Use
Four rapid tests approved by the U.S. Food and Drug Administration (FDA) can provide rapid results
during labor and delivery: the OraQuick Rapid HIV-1 Antibody Test (OraSure Technologies, Inc.,
Bethlehem, Pennsylvania), the Reveal Rapid HIV-1 Antibody Test (MedMira Laboratories, Inc.,
Halifax, Nova Scotia), the Uni-Gold Recombigen HIV Test (Trinity Biotech Plc., Co Wicklow,
Ireland) and the Murex-SUDS-Single Use Diagnostic System HIV-1 Antibody Test (Abbott Labora-
tories, Abbott Park, Illinois).  The SUDS test is no longer available because manufacture was discon-
tinued in 2003.
When selecting a rapid HIV test for use during labor and delivery, it is important to consider the
accuracy of the test and the location within the institution at which testing will be performed.  Tests
that require serum or plasma (i.e., Reveal and SUDS) are more suitable for use in the laboratory
because of the need to centrifuge the blood specimen, whereas tests that can be performed with
whole blood (e.g., OraQuick, Uni-Gold) without specimen processing are more easily performed in
the labor and delivery unit. The sensitivities and specificities, according to clinical licensure data
submitted to the FDA, are shown in Table 1.
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Because HIV prevalence among pregnant women is low in many parts of the United States, a test
with high specificity will minimize the number of false-positive results. Comparisons of the positive
predictive values of several FDA-approved HIV-1 antibody tests in populations with differing HIV
prevalence rates are shown in Table 2.
Table 1.  FDA-approved Test Performance, by Specimen Type*
Sensitivity, % Specificity, %      CLIA
Test Specimen Type    (95% C.I.)    (95% C.I.) complexity
OraQuick Whole blood** 99.6 (98.5-99.9) 100 (99.7-100) Waived
Serum — — —
Plasma — — —
Oral Fluid — — —
Reveal Whole blood — — —
Serum 99.8 (99.2-100) 99.1 (98.8-99.4) Moderate
Plasma 99.8 (99.0-100) 98.6 (98.4-98.8) Moderate
Uni-Gold Whole blood^ 100 (99.5-100) 99.7 (99.0-100) Moderate
Serum 100 (99.5-100) 99.8 (99.3-100) Moderate
Plasma 100 (99.5-100) 99.8 (99.3-100) Moderate
SUDS Whole blood — — —
Serum 99.9 (—) 99.6 (—) Moderate
Plasma 99.9 (—) 99.6 (—) Moderate
* Data from FDA summary basis of approval
** Fingerstick and venipuncture
^ Venipuncture only
Note: SUDS has not been available since August 2003.
                                 Estimated Positive Predictive Value, %
HIV OraQuick Reveal Uni-Gold Single SUDS
Prevalence, % (blood) (serum) (blood) EIA (serum)
10 100 92 97 98 96
5 100 85 95 96 91
2 100 69 87 91 80
1 100 53 77 83 67
0.5 100 36 63 71 50
0.3 100 25 50 60 38
0.1 100 10 25 33 18
*Based on point estimate for specificity from FDA summary basis of approval. In practice, the specificity and actual
PPV may differ from these estimates.
Note. Trade names are for identification purposes only and do not imply endorsement by the US Department of Health
and Human Services or the Centers for Disease Control and Prevention.  EIA, enzyme immunoassay; SUDS, Single
Use Diagnostic System.
Table 2. Positive Predictive Value of a Single Screening Test for HIV in Populations
with Differing HIV Prevalence*
Based on the specificity observed in clinical licensure trials, the number of false-positive results
would be substantially fewer with OraQuick than with either a single enzyme immunoassay, Uni-
Gold or the Reveal rapid test. In fifteen hospitals participating in the MIRIAD study, the prevalence
of HIV ranged from 0.3% to 3% among women with unknown HIV status who consented to HIV
testing in labor and delivery.
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E. Training Labor and Delivery Staff in Rapid Testing
Whether or not point-of-care testing is performed, labor and delivery staff will be called upon to
provide women in labor whose HIV status is unknown with information on the availability of rapid
HIV testing and perinatal HIV prevention and also to inform them that they will be tested unless they
decline. (See section IV. for training essentials for persons performing the test.)
III. Key Elements of a Model Protocol for Rapid Testing during
Labor and Delivery
A.  Determining Eligibility for Rapid HIV Testing
The prenatal records of all women presenting to the labor and delivery unit should be reviewed for
documentation of an HIV test result during the current pregnancy. Any woman without documenta-
tion of an HIV test result during the current pregnancy should be routinely screened for HIV by the
use of a rapid HIV test and an opt-out approach (see section III. C). Including a standing order (e.g.,
“provide routine rapid HIV testing if there is no documentation of prenatal HIV test results unless the
woman declines”) as part of the admission orders for women in labor may also save valuable time.
Clinicians may use an opt-out approach to rapid HIV testing to re-screen women with documented
negative HIV test results during the current pregnancy if there are indications that the woman is at
continued risk for HIV infection (e.g., a history of sexually transmitted diseases [STDs], exchange of
sex for money or drugs, multiple sex partners during the current pregnancy, use of illicit drugs, sex
partner[s] known to be HIV-positive or at high risk, or signs and symptoms of seroconversion). This
approach is similar to that used for syphilis screening, in which retesting for syphilis during the third
trimester and again at delivery is recommended for pregnant women at high risk.13 Some states
mandate syphilis screening at delivery for all pregnant women. Routine universal retesting for HIV
by the use of an opt-out approach should be considered in health care facilities in areas with high
HIV seroprevalence among women of childbearing age.14
B. Ensuring Confidentiality of Pregnant Women
Protecting the confidentiality of the pregnant woman who receives HIV testing during labor is
required both by ethical standards and legal requirements. However, in the busy and complex labor
and delivery unit, maintaining confidentiality requires that staff members be knowledgeable and
vigilant. The following are practical tips to help protect the confidentiality of women who receive
rapid HIV testing during labor and delivery:
• Discuss HIV testing when the woman is alone and feels safe to answer honestly:  spouses,
partners, and other family members may not know her sexual, reproductive or HIV testing
history and this information should not be disclosed to them.
• Set up services as part of the rapid testing protocol to make available a professional inter-
preter, rather than family members, to protect the confidentiality of women who do not speak
English.
• Ask the woman in labor ahead of time whom, if anyone, she would like present when the
results of the HIV test are provided. Confidentiality should be maintained when giving
results, and only the persons the woman has indicated should be present when the test results
are provided.
• Ensure confidentiality when discussing ARV prophylaxis if the test result is positive.
• Label intravenous ARV medications in a way that protects confidentiality.
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• Develop and implement procedures to ensure the confidentiality of HIV test results received
in the labor and delivery unit. Some hospitals maintain a logbook in which to record the
following information: the patient’s medical record number, date and time that the HIV test is
done in the unit or sent to the laboratory, date and time the test results are received, and
notation that the test results have been documented in the chart or communicated to the
postpartum unit if the patient has given birth and been transferred. The system should both
maintain confidentiality and ensure that results are communicated promptly to clinical staff.
C. Suggested Approaches to Routine Rapid HIV Testing during Labor
and Delivery for Women of Unknown HIV Status: Considerations in
Implementing the Opt-out Approach
CDC recommends routine rapid HIV testing for women in labor whose HIV status is unknown
(women with no documentation of a prenatal HIV test in their medical records) unless they decline
testing, that is, unless they opt out (Appendix A, CDC, Dear Colleague Letter, April 22, 2003; also
available at: http://www.cdc.gov/hiv/PROJECTS/perinatal/2003/letter.htm). CDC also recognizes
that regulations, laws, and policies regarding the HIV screening of pregnant women and neonates are
not standardized throughout US states and territories. Health care providers and other hospital staff
developing a rapid testing protocol for their facility should be familiar with, and adhere to, state and
local laws, regulations, and policies concerning the HIV screening of pregnant women and neonates.
They should document in the medical chart the results of all tests, both the rapid and the confirma-
tory.  If a woman in labor and of unknown HIV status refuses rapid HIV screening, her refusal should
likewise be noted in the medical chart.
The following information should be given to a woman in labor whose HIV status is unknown
so that she has sufficient information to make an informed decision about screening:
1. She should be informed that the HIV virus can be transmitted from a mother to her infant
during pregnancy, during labor and delivery, and through breastfeeding and that effective
interventions during labor and after birth can substantially reduce the risk that her baby will
become infected.
2. She should be informed that rapid HIV testing will be done routinely to help protect her
infant’s health unless she declines testing.
3. She should be informed that a negative rapid HIV test result means that she is most probably
not HIV infected, but that the test cannot detect very recent infection or recent exposure. A
positive rapid test result is preliminary and a confirmatory test will need to be done.
4. She will be offered medicines right away for both her and her baby to reduce the chance that
her baby will become infected. If the confirmatory test is also positive, she will be offered
medical care for her own health.
All efforts should be made to determine a mother’s HIV status as soon as possible during labor. If
the mother’s HIV status remains unknown at delivery, she or the infant or both should have rapid
HIV testing as soon as possible postpartum. Some states mandate HIV screening of the neonate in
this circumstance; however no states mandate screening of mothers.
Providing information about HIV infection to women in labor whose HIV status is unknown and
routinely conducting rapid HIV testing are challenging, but the obstacles can generally be overcome
with a thoughtful and systematic approach.
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CDC recommends routine rapid HIV testing by the use of an opt-out approach, in which women are
informed that HIV testing will be routinely done if her HIV status is unknown during labor and
delivery but that she may decline testing (Appendix A,CDC, Dear Colleague Letter, April 22, 2003,
available also at: http://www.cdc.gov/hiv/PROJECTS/perinatal/2003/letter.htm). (For an example of
a script for an opt-out approach, see Appendix B.)  Recognizing that some jurisdictions may still
require written, signed informed consent for HIV testing, a sample written informed consent docu-
ment (opt-in; also included in Appendix B) may be useful during the transition to routine HIV testing
during labor and delivery.
The François-Xavier Bagnoud Center (FXBC), of the University of Medicine and Dentistry of New
Jersey is an internationally recognized organization dedicated to improving the lives families in-
fected and affected by HIV infection. FXBC has developed a formula for offering routine rapid
testing. (For an adaptation of this forumla, see Appendix C, which incorporates both the content that
must be covered and the process still required by some state laws.)
D.  Currently Approved Rapid HIV Test Kits
Two of the 4 rapid HIV antibody tests currently approved by the FDA are available for clinical
use: the OraQuick Rapid HIV-1 Antibody Test and the Reveal HIV-1 Antibody Test. The Uni-Gold
Recombigen HIV Test is expected to become available shortly.  The availability of rapid HIV tests
will change as new devices are developed and approved by the FDA and marketed by manufacturers.
Information on the availability of rapid HIV tests is routinely updated on the CDC Web site, at
www.cdc.gov/hiv/rapid_testing/ and is also available on the FDA Web site, at http://www.fda.gov/
cber/products/testkits.htm. The manufacturer’s instructions for rapid HIV tests should be strictly
followed.15,16
E. Interpreting Preliminary and Confirmatory Testing Results
Test results from rapid HIV tests are interpreted the same as other HIV screening test results.
• A negative result from a single test is considered negative. However, if the person being
tested may have been exposed to HIV within the past 3 months, a repeat test at a later time is
recommended because the rapid antibody test may not show very recent infection.
• A positive (or reactive) result from a rapid HIV test is considered a preliminary positive and
must be followed up with a confirmatory test, either a Western blot or an immunofluores-
cence assay (IFA). Confirmatory testing should be done as soon as possible.
• When the results of a rapid test and a confirmatory test are discrepant, both the rapid and
confirmatory test should be repeated, and consultation with an infectious disease specialist is
recommended.
F. Providing Results
When the rapid HIV test is discussed, the woman should be told how soon to expect the results.
Usually, test results will be available before delivery and are given to the woman during labor, at
which time she is asked to consent to antiretroviral prophylaxis if the preliminary result is positive. A
woman may state that she doesn’t want to be told the result of the rapid HIV test until after the
baby’s birth. In such an instance, consent for the initiation of prophylaxis should be obtained when
testing is discussed. If possible, the clinician who discussed the HIV test should give the results.
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Privacy during the discussion of test results is essential to ensure confidentiality. The woman’s
physical comfort should be assessed and monitored while she is being given test results.
Providing NEGATIVE rapid HIV test results
If the rapid test result is negative, no further medical intervention is necessary. The woman should be
told that that she is most likely not infected with HIV but that the test may not show recent infection.
The clinician should ask whether she is concerned about any recent specific risk of exposure; if she
is concerned, the clinician should recommend retesting after 3 months if indicated. More extensive
HIV counseling should be set up for her during the postpartum period, and she should be told of
these arrangements.
Providing POSITIVE rapid HIV test results
If the rapid HIV test result is positive, the clinician should tell the woman that she is likely to have
HIV infection and that the baby may be exposed to HIV. She should be assured that a second test is
being done right away to confirm the rapid test result but that the results will not likely be available
before delivery. The clinician should explain that the rapid test result is preliminary and that false-
positive results are possible but that it would be best to start ARV prophylaxis as soon as possible to
reduce the risk of HIV transmission to the baby. The medication regimen that will be offered to the
woman and her baby should be explained, including the known effects and possible adverse effects,
and she should be given the opportunity to ask questions before accepting it. She should also be told
to postpone breastfeeding until the confirmatory results are available because she should not
breastfeed if she is HIV infected. The clinician should explain that all ARV prophylaxis will be
stopped if the confirmatory test result is negative.
Preliminary results may not be available before delivery if labor is rapid or the woman is admitted to
the unit late in labor. If the preliminary HIV test result is positive, ARV prophylaxis for the neonate
should be initiated as soon as possible. (See Section G, for information on peripartum clinical man-
agement, scenario 4)
If the confirmatory HIV test result is positive, antiretroviral prophylaxis for the infant, to help pre-
vent perinatal transmission, will be continued.
If the rapid HIV test result is positive, complicated and sensitive information needs to be explained
privately to the woman during labor, a very vulnerable time. The clinician should allow time for
questions and assure her that with her permission, every measure will be taken to reduce the infant’s
risk of acquiring HIV. She should also be reassured that effective treatment is available to help keep
her healthy while she is raising her child.
In some settings, the results of the confirmatory Western blot or IFA will be available after the
mother and her infant are discharged from the hospital. As part of discharge planning, the woman
should be informed of the importance of returning to discuss her confirmatory test result so that both
she and her infant can receive appropriate medical care. A system for contacting women who miss
appointments to receive their confirmatory test results is important, especially for women who did
not receive prenatal care. Involving family members or other support persons in discharge planning
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can be helpful if the woman agrees to their participation and has disclosed her rapid HIV test results
to them.
G. Peripartum Clinical Management of Women with Positive Rapid HIV
Test Results
The US Public Health Service Perinatal HIV Guidelines Working Group publishes Recommenda-
tions for Use of Antiretroviral Drugs in Pregnant HIV-1–Infected Women for Maternal Health and to
Reduce Perinatal HIV-1 Transmission in the United States. The recommendations are available as a
living document (frequently updated) at www.aidsinfo.nih.gov/guidelines/. Given the potential
complexity of the clinical management decisions, it is strongly encouraged that local protocols for
peripartum intervention for women whose HIV infection is diagnosed during labor be developed in
consultation with HIV/infectious disease experts.
The current recommendations (version dated November 26, 2003) present 4 clinical scenarios and
ARV treatment recommendations to reduce perinatal transmission. Scenarios 3 and 4 (summarized in
the following sections) apply to women who arrive in a labor and delivery with undocumented HIV
status and who have positive rapid HIV test results. In initiating rapid HIV testing and treatment
protocols, hospital staff should access www.aidsinfo.nih.gov/guidelines/ to ensure that they follow
the most recently updated recommendations. When hospital policy is being developed, input from
clinicians with expertise in perinatal HIV management is encouraged.
HIV-infected women in labor with no prior treatment
(The following is a summary of scenario 3 from the USPHS guidelines.)
Several effective ARV treatment regimens are available, including (1) zidovudine (ZDV)
monotherapy, (2) ZDV plus lamivudine (3TC), (3) nevirapine (NVP) monotherapy, and (4) ZDV plus




Intrapartum IV ZDV (loading dose
[2 mg/kg] for 1 hour, followed by
continuous infusion [1mg/kg/hr] until
delivery)
Neonate
ZDV syrup (2 mg/kg) orally every 6
hours for 6 weeks, beginning 8–12
hours after birtha
Note. IV, intravenous; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine.
a ZDV dosing for infants of <35 weeks gestation at birth is 1.5 mg/kg/dose orally, every 12 hours,
increasing to every 8 hours at 2 weeks of age if >30 weeks gestation at birth or at 4 weeks of age
if <30 weeks gestation at birth.17
b If the mother received NVP less than 1 hour before delivery, the neonate should be given 2 mg/kg
of oral NVP as soon as possible after birth and again at 48–72 hours.
Table 3. Antiretroviral regimens for HIV-infected women in labor with no prior therapy.
ZDV (600mg) po and 3TC (150 mg)
orally at onset of labor, followed by
ZDV (300 mg) orally every 3 hours
and 3TC (150 mg)  orally every 12
hours until delivery
Single dose of NVP (200 mg) orally
at onset of laborb
Intrapartum IV ZDV (loading dose [2
mg/kg] for 1 hour, followed by [1
mg/kg/hr.] until delivery) and single





ZDV syrup (4 mg/kg) and 3TC (2
mg/kg) orally every 12 hours for 7
days
Single dose of NVP 2 mg/kg
48–72 hours after birth
ZDV syrup (2 mg/kg) orally every 6
hours for 6 weeks, beginning 8–12
hrs after birth and single dose of
NVP (2 mg/kg) orally 48–72 hours
after birth
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During the immediate postpartum period, the woman should have appropriate assessments (e.g.,
CD4+ count and HIV-1 RNA copy number) to determine whether ARV treatment is recommended
for her own health.
A description of recommended intrapartum and postpartum treatment regimens for women identified
in labor (USPHS guidelines, scenario 3) is available at www.aidsinfo.nih.gov/guidelines/ and in-
cludes data on transmission and the advantages and disadvantages of each regimen. The selection of
a specific abbreviated ARV prophylaxis regimen may be based on the resources of the institution or
the facility and an individualized clinical assessment of the patient.  Clinicians should also weigh the
potential for future NVP resistance when considering treatment options.
Infants born to mothers who have received no antiretroviral therapy during pregnancy or
intrapartum (Summary of scenario 4 of the USPHS guidelines)
• The 6-week neonatal ZDV component of the ZDV chemoprophylactic regimen should be
discussed with the mother and recommended for the neonate.
• ZDV for the neonate should be initiated as soon as possible after birth¯preferably within
6–12 hours.
• Some clinicians may choose to use ZDV in combination with other antiretroviral drugs,
particularly if the mother is known or suspected to have ZDV-resistant virus. However,
the efficacy of this approach for the prevention of transmission is unknown, and appropri-
ate dosages for neonates are incompletely defined.
• During the immediate postpartum period, the woman should undergo appropriate assess-
ments (e.g., CD4+ count and HIV-1 RNA copy number) to determine whether ARV
treatment is required for her health.  The neonate should undergo early diagnostic testing
so that if the neonate is HIV infected, treatment can be initiated as soon as possible.
Note: Discussion of treatment options and recommendations should not be coercive, and the final
decision about the use of ARV prophylaxis is the mother’s. The selection of a specific, abbreviated
course of ARV prophylaxis may be based on the resources and policies of the institution or the
facility, as well as an individualized clinical assessment of the patient.
Intrapartum care
If labor progresses and membranes are intact, artificial rupture of membranes and invasive monitor-
ing should be avoided. Labor should be managed with spontaneous rupture of membranes (SROM).
Episiotomy should be avoided if clinically appropriate. Breastfeeding should also be avoided.
Cesarean section
Women diagnosed with HIV infection through rapid testing at the time of presentation for delivery
will frequently present in active labor and/or with ruptured membranes.  In such circumstances,
information regarding maternal viral load will likely not be available to guide the management of
delivery. Data are insufficient to indicate whether cesarean section (C-section) will add any benefit in
reducing the risk of MTCT.18 In the only published randomized controlled trial of c-section in HIV-
infected women, rates of perinatal HIV transmission between mother-infant pairs with emergency C-
section (after active labor or rupture of membranes) and mother-infant pairs with vaginal delivery did
not differ.19 However, for women whose HIV infection was diagnosed late in pregnancy and who
have no evidence of labor or rupture of membranes but who have clinical indications for delivery
(e.g. preeclampsia, vaginal bleeding, fetal heart rate abnormalities, intrauterine growth retardation,
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ 15
oligohydramnios), c-section may help to prevent HIV transmission.  Management in such circum-
stances should be individualized, and accepted principles should be taken into consideration:
1. The greatest benefit in preventing transmission is associated with cesarean delivery per-
formed before the rupture of membranes or to the onset of labor in conjunction with the
administration of ARV prophylaxis.
2. ARV prophylaxis should be administered to the woman before cesarean delivery whenever
possible (ideally, 2–4 hours).
A more comprehensive discussion of the role of C-section in the prevention of perinatal HIV trans-
mission is available in the U.S. Public Health Service Task Force Recommendations for Use of
Antiretroviral Drugs in Pregnant HIV-1–Infected Women for Maternal Health and Interventions to
Reduce Perinatal HIV-1 Transmission in the United States (www.aidsinfo.nih.gov/guidelines/).
Neonatal care
• The neonate should be bathed promptly after birth and before injections (e.g., vaccines or
vitamin K).
• A baseline complete blood count (CBC) with differential AND serum chemistries should be
performed before initiating ARV prophylaxis. A CBC should be repeated at 6 and 12 weeks
of age.
• Polymerase chain reaction (PCR) testing for HIV-1 should be done at birth (before 48 hours
of age) and repeated at ages 1–2 months and 3–6 months. Additional testing at 14 days of age
might allow the early detection of infection.20
*HIV-exposed infants should be evaluated by, or in consultation with, a specialist in HIV infection in
pediatric patients. Regular updates of the Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection are available at www.aidsinfo.nih.gov/guidelines.
H. Communication with Pediatricians
It is crucial that the obstetric provider communicate with the pediatric provider when a neonate has
been exposed to HIV.  The medical care of an HIV-exposed infant is different than that of an infant
who has not been exposed to HIV. In some states, regulations ensure that the obstetric provider’s
communication of the mother’s HIV status to the pediatric provider is not considered a breach of
confidentiality.
I. Referral for Follow-up of HIV-infected Mother and HIV-exposed Infant
Both mother and infant need to be referred for ongoing care to providers with experience and exper-
tise in HIV care. Services for families affected by HIV infection are available in many communities
through Title IV or Title III of the Ryan White CARE Act. HIV-infected mothers who are just learn-
ing their HIV status or who have not been in care need a thorough evaluation of their immune and
clinical status and assessment of their need for ARV treatment or other care. Infants need diagnostic
testing and clinical monitoring to determine their HIV status. All infants exposed to HIV should be
placed on an antibiotic for prophylaxis against Pneumocystis carinii pneumonia (PCP) at 6 weeks of
age, and should continue to receive it until it has been confirmed that they are not infected with
HIV.20  Families need access to case management and psychosocial support services, ideally through
a comprehensive, family-centered HIV program. In some communities, a case manager from the
family HIV care program will visit the mother in the hospital if notified of the referral.
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Before discharge, the mother should be educated about the ARV prophylaxis and why it is important
that the infant complete the full course of medication. Teaching should emphasize that (1) the infant
must complete the ARV prophylaxis, (2) the infant should begin taking antibiotic prophylaxis for
PCP at 6 weeks of age, (3) the infant will need further testing during the first few months of life to
determine HIV status, and (4) the mother should return to receive confirmatory HIV test results (if
not received before discharge). If the mother has disclosed her HIV status to a family member or
other support person, it is beneficial to involve the support person in instructions about the necessary
follow-up care of both mother and infant.
J. Reporting HIV/AIDS
If Western blot or IFA test results confirm HIV infection, the facility must follow all applicable local
and state requirements regarding the reporting of HIV infection or AIDS.  If personnel are uncertain
about the HIV/AIDS reporting requirements in their area, they should contact their state health
department HIV/AIDS surveillance unit.
IV. Management Considerations in Developing and Implementing a
Facility-based Rapid HIV Testing Protocol for Women in Labor:
Preparation and Training
A. Key Players
Training is essential when introducing a new procedure to labor and delivery care. The entire patient
care team should be educated about rapid HIV testing during labor. The hospital laboratory staff
should be involved in developing and maintaining a quality assurance program.
B. Training of Labor and Delivery Staff--Rapid HIV Testing for Women
in Labor
It is essential to provide ongoing training for labor and delivery staff in providing information about
HIV infection and rapid testing for women in labor whose HIV status is unknown.  Without such
training, many nurses, obstetricians, nurse-midwives, residents, and house staff may not have up-to-
date information about perinatal HIV transmission or the experience, comfort, or skill to use sensitiv-
ity when providing women with accurate information about rapid HIV testing or to perform rapid
HIV testing during labor and delivery.
Who should be trained
Training in rapid HIV testing and intrapartum or neonatal ARV prophylaxis to reduce perinatal HIV
transmission should be available for all staff who provide care for pregnant women, women in labor,
and neonates. These staff members include obstetricians, residents and house staff, family practice
physicians, nurse-midwives, labor and delivery nurses, perinatal nurse educators and managers,
nurse practitioners, pediatricians, and infection control practitioners.
In nonteaching hospitals, the labor and delivery nurse is the person most likely to assess the woman’s
medical record for documentation of HIV testing and to provide the woman with information about
rapid HIV testing. In teaching hospitals, medical residents, house staff, obstetricians, or nurse-
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midwives are most likely to have the responsibility for offering rapid testing. However, the labor and
delivery nurse plays an important role in admission assessment, patient teaching, and support.
Content
The training should include the following:
• The failure of risk-based HIV testing to identify HIV-infected pregnant women
• Local, regional, and national HIV/AIDS statistics for women
• CDC guidelines for HIV testing for women in labor
• Factors that influence perinatal HIV transmission
• Interventions to reduce transmission during labor and postpartum
• Short-course ARV prophylaxis for mother and infant
• Strategies to ensure confidentiality
• Approaches to providing information during labor
• Methods for interpreting rapid test results
• Local referrals and follow-up care for the HIV-infected woman and her infant
Training in ARV prophylaxis should include the options for preventing MTCT, strategies for ensur-
ing the availability of medication, specifics of medication administration for mother and infant, and
teaching and follow-up for mother and infant.
Teaching strategies and methods for staff: Didactic or independent learning (computer-based or
Web-based) works well for HIV statistics, factors that influence perinatal transmission, current
research, treatment to reduce perinatal transmission, and specifics about the rapid test.
Case-study discussion in small groups can be the best approach for skill building and problem
solving and for exploring attitudes. One or two cases can be discussed in approximately 30 minutes.
Role-playing can be used separately or with case-study discussion to practice discussions about
rapid testing of the mother during labor or rapid testing of the infant during the postpartum period.
One session of role-playing can usually be completed and discussed in 30?–45 minutes.
Opportunities to provide training
The busy labor and delivery suite does not offer many opportunities for formal in-service training.
Thought is needed to present content and make it available at times that are convenient for obstetric
staff and providers.  Motivation for learning can be increased if CME (continuing medical education)
credit and nursing CE (continuing education) contact hours are provided.
In the fall of 2003, CDC funded the Health Research Education Trust, the research and education
affiliate of the American Hospital Association (www.hret.org) and the
François-Xavier Bagnoud Center (www.fxbcenter.org) to develop model policies, tools, and training
materials to assist hospitals and birthing centers implement rapid HIV testing programs in labor and
delivery units.
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C. Training Essentials for Persons Performing Point-of-Care Rapid
HIV Testing
The OraQuick rapid HIV test is used as an illustration of a test that can be performed in the labor and
delivery unit. The laboratory, medical, or nursing staff may lead the training session. Including the
following suggested points will allow trainees to:
• Review the OraQuick package insert along with the facility’s standard operating procedure.
• View the OraQuick rapid HIV antibody testing video
• Observe a demonstration of setting up the OraQuick Rapid HIV Antibody Test
• Perform a panel of 5 known specimens and obtain 100% accuracy
• Take a competency test on the OraQuick rapid HIV test¯100% accuracy or counseling
documented for incorrect answers
• The following points should be emphasized as part of training staff to carry out rapid HIV
testing:
o Handle requests for rapid HIV testing stat.
o Verify that appropriate positive and negative controls have been performed on the lot
number in use and match expected results before setting up a patient’s specimen.
o Read the OraQuick Test 20 minutes after setup.  Do not exceed 40 minutes. A timer can
be clipped onto one’s uniform to ensure that the test is read within time limit.
o Report results as soon as possible (no longer than 60 minutes after receipt of specimen).
o Document all rapid HIV test results and inform the patient’s health care provider accord-
ing to protocol.
o Refer all specimens that test preliminary positive to the appropriate laboratory for confir-
matory testing.
In October 2003, CDC began to offer a training course called Fundamentals of HIV Testing Using
the OraQuick Rapid HIV-1 Antibody Test in various locations throughout the United States. Informa-
tion about the training and a regularly updated list of the cities can be found at http://www.cdc.gov/
hiv/rapid_testing/.  In early 2004, CDC will partner with the François-
Xavier Bagnoud Center to offer regional training specific to perinatal HIV prevention, with emphasis
on rapid HIV testing in labor and delivery settings. In addition, to assist with local training, OraSure,
for example, offers a short training video about performing the OraQuick HIV-1 antibody test.
D. Ensuring Staff Proficiency and Competency to Carry Out Rapid HIV
Testing in Labor and Delivery Settings
Implementation of a rapid HIV testing program is essential to effect the quick ( no longer than 60
minutes) turnaround time of results, which is needed to offer timely prophylaxis to women in labor
whose HIV status is undocumented but whose specimens are reactive (positive) to the rapid HIV test.
All laboratories and testing sites must adhere to the minimum requirements of the Clinical Labora-
tory Improvement Act of 1988 (CLIA88).   Because of the critical clinical implications of this test
result, it is of the utmost importance to ensure accurate testing and the reporting of all results.  CDC
has developed quality assurance guidelines for performing rapid HIV testing, which are available at
www.cdc.gov/hiv/rapid_testing/.
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The keys to successful performance of rapid HIV testing and reporting are
• Clear and concise procedures
• Training of personnel
• Verification of competence of personnel
• Proper performance of quality control procedures
• Recognition of when the testing does not comply with procedures
In a laboratory, these duties would be managed by a Quality Control or Quality Assurance Compli-
ance Officer.  In a point-of-care testing (POCT) setting, it is important to establish a POCT coordina-
tor (typically a laboratorian) who is responsible for training, quality control, and quality assurance
issues.
One way to assess the capacity of the laboratory or testing site to accurately test and report rapid HIV
results is through proficiency testing, “an external program in which samples are periodically sent . . .
for analysis.”  The results from the individual participants are compared to the expected values.
Each site receives a graded individualized report and a summary report showing their performance
and the performance of all the participants.  Proficiency testing is desirable, even for the CLIA-
waived OraQuick test, because the decision to administer ARV prophylaxis will be based initially on
a single, preliminary positive result. CLIA-certified laboratories and testing sites are required to
participate in a proficiency testing program that is approved by the Center for Medicare and Medic-
aid Services for any test that is not certified by CLIA as waived (e.g., Reveal).
Another mechanism for ensuring the accuracy of test results is continued competency testing of
personnel. Competency testing refers to the periodic evaluation of a person’s ability to “perform a
test and use the testing device.”  CLIA88 requires each person who is authorized to perform rapid
HIV testing that has not been waived by CLIA (e.g., Reveal) and report results to perform compe-
tency testing semiannually the first year and at least annually thereafter. Competency testing can take
many forms, including performance of the test on known specimens, direct observation, a written
examination on the test, and a Web-based competency test. Although this testing is not explicitly
required for CLIA-waived tests (e.g., OraQuick), it is recommended to ensure competency, and it is
desirable because the decision to administer ARV prophylaxis will be based on 1 preliminary posi-
tive result of a rapid HIV test.
For testing done in the labor and delivery unit, the POCT coordinator would keep records of all
training and competency verification of personnel, quality control, patient testing, and proficiency
testing.
V. Conclusion
Until all HIV-infected pregnant women are tested for HIV infection during prenatal care, the promise
of the findings of AIDS Clinical Trials Group Protocol 076, the first study to demonstrate the effi-
cacy of an ARV medication (i.e., AZT) to substantially reduce perinatal HIV transmission, and the
findings of other important perinatal HIV prevention studies—that perinatal HIV transmission can
largely be prevented and virtually eliminated—cannot be realized. Although efforts are in place to
improve access to prenatal care, prenatal HIV testing, and ARV prophylaxis, opportunities to prevent
perinatal HIV transmission continue to be missed, and infants acquire HIV infection. The routine use
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of rapid HIV testing and medical interventions in labor and delivery settings provides a final oppor-
tunity to reduce the effect of those missed opportunities for prevention. It is recommended that
hospitals adopt a policy of routine rapid HIV testing by using an opt-out approach for women
whose HIV status is unknown when presenting to the labor and delivery. It is recognized that
implementing rapid testing programs in labor and delivery settings poses challenges. However,
clinicians in labor and delivery settings frequently make complex medical decisions, implement
emergency life-saving interventions, and discuss sensitive and difficult personal information with
patients. This document is intended to assist clinicians by adding another important tool to their
repertoire of clinical screening and HIV prevention interventions.
For inquiries or comments, e-mail Margaret A. Lampe, RN, MPH (mlampe@cdc.gov).
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CDC Perinatal HIV Prevention Web site. Available at: http://www.cdc.gov/hiv/projects/perinatal/.
Includes current CDC perinatal HIV prevention programs, current CDC recommendations
and studies on perinatal HIV prevention in the United States, and notices and summaries of
national meetings of CDC perinatal HIV prevention grantees.
CDC Rapid Testing Web site. Available at: http://www.cdc.gov/hiv/rapid_testing/.
Includes frequently asked questions about rapid HIV testing, official CDC and FDA releases,
and studies on rapid tests.
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Women and Children with HIV Web site of François-Xavier Bagnoud Center (University of
Medicine and Dentistry of New Jersey) and Center for HIV Information (University of California
San Francisco). Available at: http://www.womenchildrenhiv.org/.
Includes clinical information, training resources, and best-practice recommendations
regarding perinatal HIV prevention and pediatric HIV infection. Resources for U.S.
and international settings.
The Well Project Web site. Available at: http://www.thewellproject.com.
Includes fact sheets, data sets, summary slides, a searchable database of clinical trials, a
resource directory, and a physician network for expert discussion on treatment. Additionally,
members will be able to participate in confidential and secure discussion boards; read about
real people living with, and successfully managing, HIV; download advocacy tools; and
receive a regular e-mail newsletter highlighting the most up-to-date information about
women and HIV infection.
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Appendix A
Letter from Dr. Julie Louise Gerberding,  Director
Centers for Disease Control and Prevention
and
Dr. Harold W. Jaffee, Director
National Center for HIV, STD, and TB Prevention
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Dear Colleague:
The prevention of perinatal HIV transmission requires routine HJV screening of all pregnant women
and the use of appropriate antiretroviral and obstetrical interventions that begin during pregnancy.
Together, these actions can reduce the rate of mother-to-child HIV transmission to 2 percent or lower.
Recently, new data have emerged indicating that higher testing rates are associated with testing
strategies that routinely incorporate HIV tests in the standard battery of tests for all pregnant women.
In light of this information, the Centers for Disease Control and Prevention (CDC) recommends that
HIV testing be a routine screening procedure. CDC also recommends implementing rapid HIV
testing in postnatal settings for infants of women not tested prenatally. Considering the potential for
preventing transmission, no child should be born in this country whose HIV status, or whose
mother’s status, is unknown.
CDC published data on recent prenatal HIV testing rates in the United States and Canada in the
Morbidity and Mortality Weekly Report (MMWR,.) of November 15, 20022. This study examined
HIV prenatal testing rates associated with three different prenatal testing approaches from data
gathered from 16 states and 5 Canadian provinces. A brief description of the testing approaches and
data findings follows:
1. “Opt-in”: Pregnant women receive pre-HIV test counseling and must specifically consent to an
HIV antibody test, usually in writing. This is the most common prenatal HIV testing approach in
the United States Among eight states using the “opt-in” approach where data were collected
from medical records for 1998—1999, testing rates ranged from 25 percent to 69 percent.
Canadian testing rates in three “opt-in” provinces ranged from 54 percent to 83 percent.
2. “Opt-out”: Pregnant women are notified that an HIV test will be routinely included in the
standard battery of prenatal tests for all pregnant women, but they can decline HIV testing.
Currently, Arkansas, Michigan, Tennessee, and Texas have adopted some version of this ap-
proach In Tennessee, where this approach was used, a testing rate of 85 percent was reported.
Two Canadian provinces using this approach showed a testing rate of 98 percent and 94 percent.
3. Mandatory newborn screening: If the mother’s HIV status is unknown at delivery, newborns are
tested for maternal HIV-antibody, with or without the mother’s consent. Results must be avail-
able within 48 hours of testing. Connecticut and New York have implemented these approaches
(in combination with an opt-in approach for pregnant women). In these two states, data indicate
that prenatal testing rates rose from 52 percent to 83 percent in a seven-county area of New
York, and from 31 percent to 81 percent in Connecticut, during the periods just before and just
after implementation of mandatory newborn testing. In 2001, New York reported a statewide
prenatal HIV testing rate of 93 percent based on newborn metabolic screening of all live births.
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Centers for Disease Control
   and Prevention (CDC)
Atlanta, Georgia  30333
April 22, 2003
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Prenatal HIV Screening
Based on information presented in the MMWR, the available data indicate that both “opt-out”
prenatal maternal screening and mandatory newborn screening achieve higher maternal screening
rates than “opt-in” prenatal screening. Accordingly, CDC recommends that clinicians routinely
screen all pregnant women for HIV infection, using an “opt-out” approach, and that jurisdictions
with statutory barriers to such routine prenatal screening consider revising them.
Newborn HIV Screening
In addition, CDC encourages clinicians to test for HIV any newborn whose mother’s HIV status is
unknown. Jurisdictions should consider whether a mandatory screening policy for these infants is the
best way to achieve such routine screening. Data demonstrate that detection of HIV infection during
pregnancy through HIV testing of all pregnant women affords the best opportunity to deliver inter-
ventions when they are most efficacious. When intervention does not begin until the intrapartum or
neonatal periods, 9 percent to 13 percent transmission rates are achievable based on clinical trial and
observational data. Recent experience from the CDC funded Mother-Infant Rapid Intervention at
Delivery (MIRIAD) study indicates that HIV rapid testing of women can be done during labor, and
that antiretroviral interventions can be quickly delivered to HIV-infected mothers and their infants.
Therefore, for those women whose HIV status is unknown at labor, CDC recommends routine, rapid
testing. When the mother’s HIV status is unknown prior to the onset of labor and rapid HIV testing is
not done during labor, CDC recommends rapid testing of the infant immediately post-partum, so that
antiretroviral prophylaxis can be offered to HI V-exposed infants.
The federal Food and Drug Administration has approved three rapid HIV test kits (SUDS Oraquick
and Reveal which can be used at delivery When rapid test results are positive, antiretroviral interven-
tions can be offered to the mother intrapartum and to her infant based on the preliminary results.
Confirmatory testing should occur as soon as possible after delivery.
Sincerely,
Page 2 - Dear Colleague
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Appendix B
Providing Information to Women in Labor
with Unknown HIV Status Regarding Routine,
Rapid HIV-1 Antibody Testing
(Using an OPT-OUT Approach)
and
Sample Consent for Rapid HIV-1 Antibody Testing
in Labor and Delivery Settings for Women
with Unknown HIV Status
(Using an OPT-IN Approach)
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Providing Information to Women in Labor with Unknown HIV Status
Regarding Routine, Rapid HIV-1 Antibody Testing
(Using an OPT-OUT Approach)
Eligibility
Pregnant women in labor and delivery settings who have no documentation of HIV testing on prenatal record
or no history of prenatal care.
How to Use This Script:
The script is meant to be a guide to help you inform women in labor.
Background information/instructions are in regular type, words you can use are in italics –
[italics are hard to read – suggest reworking – perhaps putting them in quotation marks.].
It is important to show empathy while you are talking with the laboring woman – through
your body language and/or through holding her hand /touch.
Tell the woman she should signal you when a contraction is happening, so you can pause
until it is over.
Pause to verify understanding.  Adjust your terminology as needed.
Tell the woman that the discussion about HIV testing will be kept confidential.
Before discussing HIV testing, ensure that the woman is between contractions, that she is fairly comfortable,
and that she is alone (no family member or significant other is present in the room, or within hearing).  Tell
her that you are going to talk to her about HIV testing, and ask if she wants her partner or family member to
be present.
Introduction
You can begin the discussion in the following way:
We recommend HIV testing to all women in labor for whom we don’t have records of an HIV
test result during pregnancy. We do this because so much can be done to protect the babies of
women living with HIV, and to help women live a healthier, longer life. We have no record that
you had an HIV test during this pregnancy.
I have three things I am going to talk to you about:
A special HIV/AIDS test
Why this test is important for you and your baby, AND
What happens when the test result comes back
A special HIV/AIDS test
It is important for you and your baby that you have a “rapid” HIV test. HIV is the virus that causes
AIDS
This test can give us results quickly
It is a blood test that we do for all women in labor without results from a prenatal HIV test unless
they decline to have the test.
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Why the test is important
Human Immunodeficiency Virus (HIV) is the virus that causes AIDS
HIV is a serious illness that can affect a woman’s health and her baby’s health.
One of the ways HIV is spread is by unprotected sex.  Therefore, all pregnant women may be at risk
for HIV infection.
HIV can be passed from a mother to her baby during pregnancy, at delivery, and through
breastfeeding.
If you have HIV infection, rapid testing will allow you to get medication during labor and delivery to
reduce the risk of passing HIV to your baby.
Your baby will receive the same medication after birth.
Without treatment, the chance the baby will be infected is about 25%, or 1 in 4 babies.
We know if women are given medication during labor and delivery and their babies get the medica-
tion right after birth, we can reduce the risk of HIV transmission to about 10%, or about 1 in 10 babies.
What happens when the rapid test result comes back?
You will receive a preliminary result about an hour after your blood is drawn.
If the rapid HIV test is negative, no further testing is needed at this time. It is  most likely that you do
not have HIV. However, the test may not show very recent infection.
If the rapid test is negative it is OK to breast feed your baby.
If the rapid HIV test is positive
You likely have HIV infection and your baby may have been exposed to HIV
The test is a screening test that provides a preliminary result and a false-positive result can happen.
We always do a second test to confirm rapid tests that are positive
To be safe, it is  best to start medicines to help prevent transmission of HIV to your baby, while we
wait for the confirmatory test result
Experts recommend several medicines to reduce chance your baby will get HIV.  One is called AZT
and it is given through your IV fluids into your vein. The other is a pill called nevirapine.
Your doctor will decide which medicines will be best for you and your baby and will discuss them
with you before starting them.
After your baby is born, he/she will start taking AZT syrup.
These medicines have been studied for in pregnant women and newborns and there have been no
serious side effects.
Side effects that may occur with AZT are: vomiting, headache, feeling tired, anemia (low red blood
cell numbers), decreased number of white blood cells, that fight infection, loss of appetite, heartburn,
trouble sleeping. Side effects of nevirapine can be skin reactions or problems with the liver.
You should wait until we have the results of the confirmatory test before you start breastfeeding
If the confirmatory test is negative
You and your baby will immediately be taken off any medication that was started
If the test is confirmed as positive
All medication that was started to help prevent HIV transmission will continue.
If treatment is started, a doctor or nurse will discuss again any consequences of taking the medication
Your baby will need more testing for HIV infection
You will be referred to a physician for your own medical care—there are also medications to help
keep you healthy longer. You will also be referred to a health care provider who will take care of your
baby’s medical needs
HIV test results are confidential. There are laws to protect people with HIV from discrimination.
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Conduct rapid HIV testing and document the result clearly in the medical record.
If the woman declines HIV testing, probe for her reasons and help her address her concerns. If
she still declines testing, document her refusal clearly in the medical record and communicate
to her baby’s pediatrician that her HIV status is unknown.
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Sample Consent for Rapid HIV-1 Antibody Testing in Labor and Delivery
Settings for Women with Unknown HIV Status
(Using an OPT-IN Approach)
This is a sample consent form (OPT-IN) from the Francois Xavier Bagnoud Center for use in New
Jersey. Recognizing that a number of jurisdictions may still require written, signed informed consent
for HIV testing (an OPT-IN approach),  this sample informed consent document may be useful
during the transition to a more routine (OPT-OUT) approach to HIV testing in labor and delivery.
Introduction
New Jersey law mandates that all pregnant women be counseled about HIV infection and be
offered the HIV/AIDS test. In our hospital, we follow this recommendation because so much
can be done to protect the baby.
I have four things I am going to talk to you about
A special HIV/AIDS test
Why this test is important for you and your baby
How HIV is transmitted
What happens when the test result comes back
A special HIV/AIDS test
It is important for you and your baby that we offer you what is called a
“rapid” HIV test. Human Immunodeficiency Virus (HIV) is the virus that
causes AIDS.
This test can give us results quickly.
It is a blood test.  It is voluntary, and your consent is required before the
test can be done.
Why the test is important
HIV can be passed from a mother to her baby during pregnancy, at deliv-
ery, and through breastfeeding.
If you have HIV infection, rapid testing will allow you to get medication
during labor and delivery to reduce the risk of passing HIV to your baby.
Your baby will receive the same medication after birth.
Without treatment, the chance the baby will be infected is about 25%, or
1 in 4 babies.
We know if women are given medication during labor and delivery and
their babies get the medication right after birth, we can reduce the risk of
HIV transmission to about 10%, or about 1 in 10 babies.
What is HIV and how is it transmitted?
HIV is the virus that causes AIDS.
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HIV is a serious illness that can affect a woman’s health and her baby’s
health.
One of the ways HIV is spread is by unprotected sexual intercourse.
Therefore, all pregnant women may be at risk for HIV infection.
HIV can be passed from a mother to her baby during pregnancy, at deliv-
ery, and through breastfeeding.
What happens when the rapid test result comes back?
You will receive a preliminary result about an hour after your blood is
drawn.
If the rapid HIV test is negative, no further testing is needed at this time. It
most likely means that you do not have HIV. However, the test may not
show recent infection.
If the rapid test is negative it is OK to breast feed your baby.
If the rapid HIV test is positive
You likely have HIV infection and your baby may have been exposed to
HIV.
The test is a screening test that provides a preliminary result. A false-
positive result can happen.
We always do a second test to confirm rapid tests that are positive.
But if your test result is positive, it is be best to start treatment to help
prevent transmission of HIV to your baby, while we wait for the confirma-
tory test result
We will need your permission to start medications if the preliminary test is
positive.
Experts recommend several medicines to reduce the chance your baby will
get HIV.  One is called AZT. We give it to you in your IV fluids through
your vein. The other is a pill called nevirapine.
Your doctor will decide which medicines will be best for you and your
baby.
After your baby is born, he/she will start taking AZT syrup.
These medicines have been studied in pregnant women and newborns and
there have been no serious side effects.
Side effects that may occur with AZT are vomiting, headache, feeling
tired, anemia (low red blood cell numbers), decreased number of white
blood cells that fight infection, loss of appetite, heartburn, trouble sleeping.
Side effects of nevirapine can be skin reactions or problems with the liver.
You should wait until we have the results of the confirmatory test before
you start breastfeeding.
If the confirmatory test is negative
You and your baby will immediately be taken off any medication that was
started.
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If the test is confirmed as positive
All medication that was started to help prevent HIV transmission will
continue.
If treatment is started, a doctor or nurse will discuss with you again any
consequences of taking the medication.
Your baby will need more testing for HIV infection.
You will be referred to a physician for your on-going medical care. You
will also be referred to a health care provider who will take care of your
baby’s medical needs.
HIV test results are confidential. There are laws to protect the rights of
people with HIV and prevent discrimination.
Sample Informed Consent Form
Please sign your name below once you have read (or have had explained to you) and understand:
1. Antiretroviral medication may reduce the risk of HIV transmission to my baby
and this medication will be started if my preliminary HIV test result is positive.
2. A positive preliminary test will be confirmed with additional testing.
3. Refusing to be tested will not jeopardize my ongoing care or services.
4. I have been given written information about everything told to me.
I consent to be tested for HIV infection using a rapid test
If my preliminary HIV test is positive, I consent to have antiretroviral medication started
during labor and for my baby after birth
I decline to have rapid HIV testing at this time.
Name_________________________________________    Signature__________________________________________
(PRINT)
Date__________________________________________    Witness____________________________________________
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Appendix C
The François-Xavier Bagnoud Center’s
Formula for Offering Routine, Rapid HIV Testing
to Women in Labor with Unknown HIV Status
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The François-Xavier Bagnoud Center’s Formula for Offering Routine,
Rapid HIV Testing to Women in Labor with Unknown HIV Status
(Based on the mnemonic “C3R3”)
The three Cs represent confidentiality, comfort, and consent.  The three Rs are reasons for
the rapid test, results, and “Rx” for treatment, or medications to reduce mother to child
transmission.
C3
Confidentiality: It is important to reassure the woman that the discussion about HIV testing will
be kept confidential and that the information will not be shared with her partner or family with-
out her permission.
Comfort: The clinician should assess the woman’s stage of labor, comfort level, and need for
analgesics. Providers need to show empathy while presenting information about rapid HIV
testing. The content covered should be short and to the point and  should be explained between
contractions. The clinician should ask the woman to signal for a pause when a contraction is
starting. The clinician should always consider the woman’s language and culture and, as needed,
must adjust the terminology used. The clinician should make sure that the woman being coun-
seled understands the content being covered by checking after each point is made and before
beginning the next point to be sure she understands.
Consent for testing and for antiretroviral treatment, if needed, in labor: Regulations, laws, and
policies about HIV testing of pregnant women vary from state to state. Providers need to know
and need to follow the laws and policies of their state. The minimum content that should be
included in educating a pregnant woman about HIV rapid testing during labor is detailed next
under Reasons to test.
R3
Reasons to test: The woman should be informed of the important reasons to get an HIV test during
labor, and the crucial opportunity to prevent possible transmission of the virus to her unborn baby
should be emphasized:
HIV is the virus that causes AIDS. One of the ways HIV is spread is by unprotected sexual
intercourse. Therefore, all pregnant women are at risk for HIV infection.
A woman could be at risk for HIV and not know that she is at risk.
The HIV virus can be passed from a mother to her baby during pregnancy, at delivery, and
through breastfeeding.
Learning that a woman has an HIV infection while she is still in labor gives her a crucial oppor-
tunity to reduce the risk of transmitting HIV to her infant; and, just as importantly, having this
knowledge also ensures that both she and her baby receive the care and the treatment they need.
HIV testing is recommended for all pregnant women. Hospital/national policy (and/or state law)
recommends HIV testing for all women in labor with unknown HIV status.
Unless the woman refuses to be tested, our hospital routinely does rapid HIV testing for all
women in labor who don’t already have an HIV test result in their medical record.
Results
If she is tested for HIV during labor, a woman should be told when she will receive her test
results.
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A negative HIV test result means a woman almost certainly does not have HIV infection at this
time. A positive HIV test result means a woman likely has HIV infection even if she is feeling
well. Further testing will be done after she delivers to confirm if she has HIV infection.
A woman should be asked who she wants to be present when she receives her rapid HIV test
result.
Rx – Medications
Medications can reduce the risk of transmission of HIV to the baby. Without medication, the
chance the baby will be infected is about 25%—or about 1 baby in 4 births could be infected
with HIV. With the medications given to the woman during labor and to the newborn, the risk of
HIV transmission can be reduced to about 10— or to about 1 baby out of 10  births.
If a woman is found to have HIV infection, treatment is available to help keep her well.
Any medication will be stopped if the confirmatory HIV test result is negative.
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Appendix D
Boxed Case Studies:
Development of a Statewide Standard of Care:
The New Jersey Experience
and
A Review of the Implementation of
Perinatal HIV Rapid Testing
Medical Center Of Louisiana, New Orleans
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Development of a Statewide Standard of Care:
the New Jersey Experience
Sindy M. Paul, M.D., M.P.H.
New Jersey is a high prevalence state for HIV disease, ranked fifth in the country in cumulative
reported AIDS cases, third in the country in cumulative reported pediatric AIDS cases, and first in
the country in the proportion of women among reported cumulative AIDS cases.  Ninety-four percent
of the pediatric AIDS and HIV cases are attributed to perinatal transmission.
The approach taken by the New Jersey Department of Health and Senior Services (NJDHSS) was to
conduct a needs assessment to determine the major missed opportunity to reduce vertical transmis-
sion, develop a the standard of care in collaboration with stakeholders with consensus facilitated by
meeting with stakeholders individually (i.e. meetings with the obstetrical society), dissemination of
information, and evaluation of implementation and effectiveness.
Needs Assessment
The need for a statewide standard of care for women who present in labor with the delivery team
unaware of her HIV status was determined based on several factors.  These include
1) A review of missed opportunities that indicated that currently the major barrier to maxi-
mal reduction of vertical HIV transmission in New Jersey is women who present in labor with
unknown HIV status;
2) Advances in HIV diagnostic testing technology and medical management that led to recent
national recommendations that women who present in labor with unknown HIV status should
receive counseling, be offered rapid HIV diagnostic testing, and, if HIV positive, be offered short
course therapy;
3) Results of a study that was conducted in the highest risk areas in New Jersey that determined that
none of the hospitals providing obstetrical care had policies, procedures, or laboratory capability
to provide counseling and offer rapid testing and short course therapy; and
4) Meetings with two ad hoc advisory committees of stakeholders.
Working with Stakeholders
• Two ad hoc advisory committees were developed and met to 1) determine if a statewide approach
was appropriate and 2) to develop the prototype policy and algorithm that facilities providing
obstetrical care could implement for women who present in labor with unknown HIV serostatus.
• One ad hoc advisory committee consisted of stakeholders responsible for writing and implement-
ing the Standard of Care.  This ad hoc advisory committee included representatives from the New
Jersey Department of Health and Senior Services (Division of AIDS Prevention and Control and
the Division of Family Health Services), obstetricians, pediatricians, Title IV providers, the New
Jersey Family-Centered HIV Care Network, case managers, social workers, consumers, maternal
and child health consortia, infection control professionals, the Academy of Medicine of New
Jersey, the AIDS Education and Training Center, and Medicaid.  This committee met three times.
The unanimous decision was that a statewide Standard of Care was the best approach to take in
New Jersey.  The committee felt that the NJDHSS should be the lead on developing, disseminat-
ing, and evaluating the Standard of Care. In the fall of 2001, the NJDHSS approved the draft of
the Standard of Care for Women Who Present in Labor With Unknown HIV Status, which was
written with the ad hoc advisory committee.
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• The second ad hoc advisory committee consisted of stakeholders responsible for facilitating
implementation of the Standard of Care. This ad hoc advisory committee included representa-
tives from the New Jersey Department of Health and Senior Services (Division of AIDS Preven-
tion and Control and the Division of Family Health Services), the Medical Society of New
Jersey, all three hospital associations in New Jersey, the Infectious Diseases Society of New
Jersey, the New Jersey Association of Osteopathic Physicians and Surgeons, New Jersey Section
of the American College of Obstetrics and Gynecology, the New Jersey Obstetrical and Gynecol-
ogy Society, the New Jersey Section of the American Academy of Pediatrics, the New Jersey
Academy of Family Physicians, pediatric and obstetrical providers with a high-volume client
load. This committee met once and provided written comments on the draft Standard of Care.
They concurred with the other committee that NJDHSS should take the lead on developing,
disseminating, and evaluating the Standard of Care. The unanimous decision was that a statewide
Standard of Care was the best approach to take in New Jersey.
• Individual meetings were held with some key organizations such as the New Jersey Obstetrical
and Gynecology Society, the Infectious Diseases Society of New Jersey, Medicaid, the NJDHSS
Laboratory Task Force, and the Association for Professionals in Infection Control and
Epidemiology.
• A one-on-one meeting was held with a high-volume facility in a high-prevalence area to help
ascertain the potential barriers to implementing a statewide Standard of Care.
• Support for the statewide Standard of Care was obtained from the Governor’s Advisory Council
on AIDS.
Identification and Overcoming Barriers
Several barriers were encountered in implementation of the standard of care.  The first barrier was
that the advisory committee members did not have enough information on rapid testing.  To over-
come this obstacle, a half-day continuing medical education conference with a didactic lecture on
rapid testing by Dr. Bernard Branson from CDC and case studies of women who presented in labor
with unknown HIV status preceded the advisory committee meeting.  The committee then felt that
they had enough information on rapid testing to proceed with development of the standard of care.
The second barrier was that providers were uncertain about the content of counseling for women in
labor.  To overcome this, a template counseling session was developed with assistance from focus
groups composed of postpartum women.  The template counseling session was disseminated state-
wide through five train-the-train sessions conducted in collaboration with all the local maternal-child
health consortia.
The third barrier identified was that hospital laboratory directors were under the misimpression that
preliminary positive rapid or expedited test results could not be given to the providers and patients.
To overcome this, a fact sheet on rapid testing was sent to each hospital with other information
related to the standard of care, information was provided in a series of lectures given statewide, and
an article was published in New Jersey Medicine.
The fourth barrier was that some hospitals requested a template policy to use.  This was provided to
them.
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Dissemination of the Statewide Standard of Care
A multimedia comprehensive approach is underway to disseminate the Standard of Care.   This
consists of free Internet-based continuing medical education (available at www.acadmed.org), publi-
cation of articles in New Jersey Medicine, publication of articles in AIDSLine, a laminated pocket
card for providers, poster presentations, train-the-trainer sessions, and continuing medical education
lectures statewide.  A mailing was sent to the chair of pediatrics, the chair of obstetrics, the labora-
tory director, the infection control professional, the chief executive officer, the medical director, the
head nurse for labor and delivery, the executive committee, the vice-president of risk management,
and the emergency room director of each hospital.  The information packet included a cover letter
from the Deputy Commissioner, the Standard of Care, the laboratory alert, the laboratory algorithm,
and information on continuing medical education and train-the-trainer sessions.
Evaluation
Evaluation will be conducted to look at process measures and outcome measures.
• Repeat the hospital survey to determine if the Standard of Care has been incorporated into hospi-
tal policies and procedures and identify barriers to its implementation
• Retrospective medical record review to evaluate the implementation and effectiveness of the
Standard of Care
• Continuous evaluation of efforts to reduce vertical transmission through surveillance, survey for
childbearing women, and special studies.
Funding
Funding to develop, disseminate, and evaluate the Standard of Care came from state and federal
funds.  These funds allowed NJDHSS to contract with the National Pediatric and Family HIV Re-
source Center to help develop the counseling session, conduct the train-the-trainer sessions, provide
three of the continuing medical education programs, and evaluate the implementation and effective-
ness of the Standard of Care.
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Review of the Implementation of Perinatal  HIV Rapid Testing
Medical Center of Louisiana, New Orleans
Robert T. Maupin, M.D.
This is a summary of the initial clinical experience with the SUDS assay, for obstetric rapid testing,
at the Medical Center of Louisiana.
In October of 1998, the Medical Center of Louisiana, New Orleans (formerly Charity Hospital),
initiated rapid HIV-1 screening for obstetric patients admitted to the labor and delivery unit without
prior documentation of HIV status. This program was approved by the Hospital Executive Commit-
tee and was established in conjunction with the use of rapid screening for employee occupational
exposures. The program was developed by the hospital’s Infection Control Division to address
disease prevention and health care delivery needs of a subgroup of obstetric patients shown to have a
two- to threefold greater HIV seroprevalence as compared with patients receiving obstetric prenatal
care in the hospital’s clinics.  As a standard of care, all obstetric patients presenting to the labor and
delivery unit with an undocumented HIV serostatus are offered voluntary HIV testing.  Patients at
risk for delivery prior to the completion of conventional HIV testing were offered initial screening
with the FDA-licensed Single-Use Diagnostic System Test (SUDS), a rapid enzyme-linked
immunosorbent assay (EIA).  Patient acceptance of HIV testing was documented with written in-
formed consent based on hospital policy and standards of care and in accordance with State guide-
lines for HIV testing at public facilities. Request for SUDS testing are submitted via the computer
laboratory entry system. Patients consenting for screening were tested concurrently with a conven-
tional HIV EIA and the SUDS HIV-1 rapid assay. SUDS assay determinations were conducted in the
hospital blood bank laboratory service.  This laboratory resource was selected based on the presence
of adequate technical staff on a 24-hour basis.  A confirmatory Western blot was used to document a
true positive HIV result. The results of the SUDS test are reported electronically via the computer-
ized laboratory inquiry system and are read out as SUDS reactive or non-reactive, and patients are
informed of their SUDS test result by their treating physician.
Patients with a positive SUDS test result were counseled by their treating physician about the impli-
cations of the presumptive HIV positive status and were counseled about options for intervention to
reduce vertical transmission of HIV.  Laboring patients were administered peripartum antiretroviral
prophylaxis consistent with the Public Health Service (PHS) guidelines. Infants delivered to mothers
with positive SUDS tests were considered HIV exposed and initiated postpartum antiretroviral
prophylaxis consistent with the PHS guidelines. When conventional HIV test results were discordant
with the SUDS test and failed to confirm infection, the newborn prophylaxis was discontinued.
All mothers with a confirmed HIV infection and their HIV-exposed infants were referred for HIV
primary care follow-up at time of hospital discharge.  The results of all obstetric patients who under-
went both conventional and rapid HIV testing were recorded in the Office of Hospital of Infection
Control’s database.
Initial laboratory implementation and training was accomplished over several months. Blood bank
technologists participated in a half-day “hands on” training session conducted by a SUDS vendor
representative.  Validation testing was conducted on site at the Medical Center of Louisiana, New
Orleans Blood Bank Laboratory.  The validation laboratory protocol required running 100
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“unknown” serum samples with positive and negative controls.  Compliance with accreditation
guidelines required an evaluation of the new testing program with a proficiency testing survey.
Subscription to the Wisconsin State Lab of Hygiene HIV Survey for HIV-1/2, formerly the Health
Care Financing Administration (now called Centers for Medicare and Medicaid Services) approved
and vendor recommended, was acquired to meet these requirements. The initial implementation cost
of the hospital program for SUDS testing was approximately $2,000.
An examination of the Hospital’s perinatal HIV rapid testing program through the first 12 months
demonstrated a SUDS test performance with a sensitivity and specificity of 100% and 99.2%, and
positive and negative predictive value of 79% and 100%, respectively. The overall seroprevalence in
the tested population was 2.9%.  The positive predictive value of the SUDS assay was highest among
laboring women with inadequate prenatal care and an undocumented HIV status, which represented
the highest seroprevalence group (>5%).
An evaluation of the initial clinical experience with perinatal HIV rapid testing demonstrated that
nearly 20% of the HIV exposed births at the facility were identified through rapid testing. The major-
ity of these mothers had inadequate or absent prenatal care.  All SUDS positive laboring mothers
with a subsequent confirmed positive HIV status had evidence of advance labor or rupture of mem-
branes at admission.  All of these mothers had inadequate prenatal care. Of note upon review of
medical records, it was determined that as many as 50% these mothers had evidence of a positive
HIV test prior to the current pregnancy, but did not disclose their HIV status to their treating physi-
cian at time of presentation. Intrapartum antiretroviral prophylaxis was successfully initiated in the
majority of these mothers, and newborn prophylaxis was initiated for all infants prior to hospital
discharge.  All infants entered HIV primary care follow-up post hospital discharge.  A preliminary
assessment of a small number of HIV-exposed infants identified with HIV rapid testing demonstrated
significantly reduced transmission rate in contrast to that expected among HIV-exposed infants
without peripartum antiretroviral prophylaxis.
This medical center’s experience highlights the capacity to effectively develop and implement
targeted strategies for perinatal HIV rapid testing in a high-seroprevalence, obstetric population, and
the potential impact of similar public health measures/interventions to reduce mother-to-child HIV
transmission among childbearing women with an undocumented HIV status and poor prenatal care.
